Skip to content

Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Citation
Web of Science 0Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2024 3.5
ISSN
2218-6751

Authors

  1. Kim, Min JeeFirst authorUniv Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
  2. Jung, JungheeUniv Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
  3. Ji, WonjunUniv Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
  4. Choi, Chang-MinUniv Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
  5. Kim, Seung JoonCatholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea
  6. Cho, Hyung JunCatholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea
  7. Hwang, Yong GiCatholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea
  8. Kim, Eun YoungYonsei Univ, Dept Internal Med, Div Pulm & Crit Care Med, Coll Med, Seoul, South Korea
  9. Lee, Shin YupKyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
  10. Yoo, Seung SooYangsan Hosp, Yangsan, South Korea
  11. Choi, SunhaKyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
  12. Oh, In-JaeChonnam Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Med Sch, Jeonnam, South Korea
  13. Kim, Young-ChulChonnam Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Med Sch, Jeonnam, South Korea
  14. Park, Chul-KyuChonnam Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Med Sch, Jeonnam, South Korea
  15. Yoon, Seong HoonPusan Natl Univ, Dept Internal Med, Sch Med, Yangsan, South Korea
  16. Kim, Yun SeongPusan Natl Univ, Dept Internal Med, Sch Med, Yangsan, South Korea
  17. Kim, Mi-HyunPusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
  18. Lee, Min KiPusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
  19. Eom, Jung SeopPusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
  20. Kim, SooHanPusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
  21. Lee, Jeong EunChungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med, Daejeon, South Korea
  22. Chung, ChaeukChungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med, Daejeon, South Korea
  23. Yeo, Chang DongCatholic Univ Korea, Eunpyeong St Marys Hosp, Dept Internal Med, Coll Med,Div Pulmonary & Crit Care M, Seoul, South Korea
  24. Lee, Sang HaakCatholic Univ Korea, Eunpyeong St Marys Hosp, Dept Internal Med, Coll Med,Div Pulmonary & Crit Care M, Seoul, South Korea
  25. Lee, Jae CheolCorresponding authorUniv Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, 88 Olympicro 43-gil, Seoul 05505, South Korea

Abstract

Background: Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors improve outcomes in EGFR T790M-positive non-small cell lung cancer (NSCLC), but the prognostic value of plasma-detected T790M remains uncertain. We evaluated the clinical significance of baseline plasma T790M in patients treated with lazertinib, accounting for metastatic distribution and coexisting genomic alterations. Methods: In this prospective multicenter cohort, we analyzed 117 patients with EGFR-mutant NSCLC who received lazertinib after T790M confirmation in tissue or plasma. Plasma EGFR mutations were profiled using next-generation sequencing before treatment. Progression-free survival (PFS) and overall survival (OS) were compared by plasma T790M status, metastatic sites, and co-alterations. Results: Of 117 patients, 92 were plasma T790M-positive and 25 were plasma T790M-negative. Plasma T790M positivity was associated with shorter PFS (10.0 vs. 23.0 months, P=0.03) and OS (20.0 months vs. not reached, P=0.006). All patients with liver or adrenal metastases were plasma T790M-positive, and involvement of either site predicted poorer outcomes than in patients without these metastases. Bone metastasis also portended a worse prognosis, irrespective of plasma T790M status. Among co-alterations, EGFR C797S or MYC alterations correlated with shorter PFS. Conclusions: Baseline plasma T790M, interpreted alongside metastatic distribution, provided prognostic information in EGFR-mutant NSCLC treated with lazertinib. Liver and adrenal metastases occurred exclusively in plasma T790M-positive patients and were associated with markedly worse outcomes, consistent with a ctDNA-shedding phenotype. Bone metastasis was an adverse prognostic factor independent of plasma T790M, underscoring the combined prognostic impact of molecular and metastatic features.

Keywords

lazertinibmetastatic distributionNon-small cell lung cancer (NSCLC)plasma epidermal growth factor receptor T790M (plasma EGFR T790M)prognosis

Identifiers

Scopus EID
2-s2.0-105028526977
WoS UID
001688005100001